Delving into the Latest Updates on Innophore GmbH with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

重组蛋白	1

排名前五的靶点	数量

ACE2(血清血管紧张素转化酶2)	1

关联

1

项与 Innophore GmbH 相关的药物

ACE2 Mutant(SignalChem Lifesciences)

靶点

ACE2

作用机制

ACE2抑制剂

在研机构

Innophore GmbH初创企业 [+1]

原研机构

SignalChem Lifesciences Corp [+1]

在研适应症

新型冠状病毒感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Innophore GmbH 相关的临床结果

登录后查看更多信息

0 项与 Innophore GmbH 相关的专利（医药）

登录后查看更多信息

18

项与 Innophore GmbH 相关的文献（医药）

2024-07-02·ChemBioChem

The Development and Opportunities of Predictive Biotechnology

Review

作者: Schürmann, Martin ; Nebel, Bernd A ; Nestl, Bettina M ; Resch, Verena ; Tischler, Dirk

AbstractRecent advances in bioeconomy allow a holistic view of existing and new process chains and enable novel production routines continuously advanced by academia and industry. All this progress benefits from a growing number of prediction tools that have found their way into the field. For example, automated genome annotations, tools for building model structures of proteins, and structural protein prediction methods such as AlphaFold2TM or RoseTTAFold have gained popularity in recent years. Recently, it has become apparent that more and more AI‐based tools are being developed and used for biocatalysis and biotechnology. This is an excellent opportunity for academia and industry to accelerate advancements in the field further. Biotechnology, as a rapidly growing interdisciplinary field, stands to benefit greatly from these developments.

2023-07-07·ACS Catalysis

A Career in Catalysis: Bernhard Hauer

作者: Syrén, Per-Olof ; Aberle, Benjamin ; Weissenborn, Martin J. ; Breuer, Michael ; Schneider, Andreas ; Nestl, Bettina M. ; Nebel, Bernd A. ; Hammer, Stephan C.

2021-02-01·iScience2区 · 综合性期刊

A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening

2区 · 综合性期刊

ArticleOA

作者: Herce, Henry D ; Namchuk, Mark N ; Moroz, Yurii ; Lewis, Noam ; Gruber, Christian ; Yust, Ryan ; Chuprina, Alexander ; Pandita, Shreya ; Kinney, Jamie ; Fischer, Patrick D ; Luxenburg, Roni ; Durmaz, Vedat ; Tesseyre, Guilhem ; Padmanabha Das, Krishna M ; Yavnyuk, Irina ; Dziuba, Igor ; Patten, J J ; Hutcheson, Colin ; Calderaio, Anthony ; Yaffe, Erez ; Rose, Alexander ; Plekhova, Alla ; Arthanari, Haribabu ; Halazonetis, Thanos D ; Radchenko, Dmytro ; Gechev, Minko ; Davey, Robert A ; Cespugli, Marco ; Fackeldey, Konstantin ; Tarkhanova, Olga ; Payne, Dave ; Leigh, Kendra E ; Shnapir, Alec ; Näär, Anders M ; Wang, Zi-Fu ; Gorgulla, Christoph ; Wagner, Gerhard

The unparalleled global effort to combat the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic over the last year has resulted in promising prophylactic measures. However, a need still exists for cheap, effective therapeutics, and targeting multiple points in the viral life cycle could help tackle the current, as well as future, coronaviruses. Here, we leverage our recently developed, ultra-large-scale in silico screening platform, VirtualFlow, to search for inhibitors that target SARS-CoV-2. In this unprecedented structure-based virtual campaign, we screened roughly 1 billion molecules against each of 40 different target sites on 17 different potential viral and host targets. In addition to targeting the active sites of viral enzymes, we also targeted critical auxiliary sites such as functionally important protein-protein interactions.

100 项与 Innophore GmbH 相关的药物交易

登录后查看更多信息

100 项与 Innophore GmbH 相关的转化医学

登录后查看更多信息